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Abstract Oxidation of methionine residues in proteins to
methionine sulfoxide can be reversed by the enzyme peptide
methionine sulfoxide reductase (MsrA, EC 1.8.4.6). We cloned
the gene encoding a human homologue (hMsrA) of the enzyme,
which has an 88% amino acid sequence identity to the bovine
version (bMsrA). With dot blot analyses based on RNA from
human tissues, expression of hMsrA was found in all tissues
tested, with highest mRNA levels in adult kidney and cerebellum,
followed by liver, heart ventricles, bone marrow and hippocam-
pus. In fetal tissue, expression was highest in the liver. No
expression of hmsrA was detected in leukemia and lymphoma cell
lines. To test if hMsrA is functional in cells, we assayed its effect
on the inactivation time course of the A-type potassium channel
ShC/B since this channel property strongly depends on the
oxidative state of a methionine residue in the N-terminal part of
the polypeptide. Co-expression of ShC/B and hMsrA in Xenopus
oocytes significantly accelerated inactivation, showing that the
cloned enzyme is functional in an in vivo assay system.
Furthermore, the activity of a purified glutathione-S-transfer-
ase-hMsrA fusion protein was demonstrated in vitro by
measuring the reduction of [3H]N-acetyl methionine sulfoxide.
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1. Introduction
The activity of proteins can be controlled by a variety of
post-translational modi¢cations such as phosphorylation,
methylation or oxidation of certain amino acids. Cysteine,
tryptophan and methionine residues within proteins can easily
be oxidized by cellular oxidants, such as hydrogen peroxide,
hypochlorite, chloramines, peroxynitrite or hydroxyl radicals
[1]. Oxidation of methionine is a two-step process, with the
¢rst step leading to the formation of methionine sulfoxide,
which, in the second step, can be further oxidized to methio-
nine sulfone under strong oxidizing conditions. While oxida-
tion to the sulfone is considered to be biologically irreversible,
the sulfoxide can be reduced to methionine by a thioredoxin-
dependent methionine sulfoxide reductase (MsrA) [2].
Methionine oxidation can alter biochemical as well as
physical properties of proteins that may be of physiological
or pathophysiological relevance. Changes in surface hydro-
phobicity in rat liver proteins were observed upon methionine
oxidation and it was suggested that this may be responsible
for age-related protein alterations [3]. Furthermore, loss of
solubility of eye lens crystallins related to cataract formation
was correlated with methionine oxidation [4]. In certain en-
zymes, methionine oxidation causes loss of functionality. For
example, inactivation of K1-proteinase inhibitor by methio-
nine oxidation is assumed to participate in the development
of smoker’s emphysema, respiratory distress syndrome and
rheumatoid arthritis (reviewed in [1,5]). In this respect,
methionine oxidation may be involved in degenerative proc-
esses.
Oxidation of methionine residues in various proteins can
also exert regulatory e¡ects on the protein function such as
(a) a decreased Ca2 and target binding of calmodulin, result-
ing in an inhibition of calmodulin-dependent activation of the
plasma membrane Ca2-ATPase [6], (b) the slowing of N-type
inactivation of ShC/B potassium channels [7,8] and (c) mod-
ulation of the activity of glutamine synthetase [9].
Therefore, MsrA may have two important functions: (a)
regulation of the protein function via oxidation/reduction of
methionine residues in proteins and (b) repair of oxidative
damage and restoration of biological activity. Overexpression
of yeast MsrA in a MsrA-de¢cient yeast strain led to better
growth in the presence of oxidizing agents. The strain also
contained less free and protein-bound oxidized methionines
than the non-transformed mutant [10]. Likewise, human T-
lymphocytes (MOLT-4), stably transfected with bovine
MsrA (bMsrA) [11], revealed increased resistance towards ox-
idative stress [12].
In rat, immunolocalization of the protein as well as North-
ern blot analysis established the presence of MsrA in virtually
all tissues investigated, though with di¡erent levels of expres-
sion [10,11], suggesting that it is important for many physio-
logical and pathophysiological events. The only mammalian
MsrA protein sequence known to date was obtained from Bos
taurus [11]. In the present study, we describe the cloning of a
human msrA gene (hmsrA) and its expression pattern. To test
functional expression, we co-injected hmsrA mRNA with ShC/
B mRNA in Xenopus oocytes. According to Ciorba et al. [7],
functionally active MsrA should keep a critical methionine in
the N-terminal ball domain of the channel in a reduced state,
thus leading to accelerated N-type inactivation. In addition,
we measured the catalytic activity of the puri¢ed protein
hMsrA in vitro.
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2. Materials and methods
2.1. Cloning of a MsrA homologue from a human cDNA library
Based on the published sequence of the bMsrA [11] and on several
partial human cDNA sequences putatively encoding homologues
found in the database of expressed sequence tags, PCR primers
were used to generate a msrA-speci¢c probe for screening a human
lung cDNA library (5P-Stretch PLUS cDNA library in VTriplEx,
Clontech, Palo Alto, CA, USA): GGAATGGGATGTTTCTGGG
(209^228), GGTCGCATGGACTCGTTCT (623^642).
Numbers in parentheses give the positions of the primer sequences
in the ¢nally determined hmsrA open reading frame.
For standard PCR (5 min 95‡C, 40 cycles of 45 s 95‡C, 45 s 57‡C,
45 s 72‡C, single extension step 5 min at 72‡C), the RedTaq poly-
merase (Sigma, Heidelberg, Germany) was used. The PCR fragment
obtained using the phage DNA from the above-mentioned library
was sequenced, thus con¢rming the speci¢city of the primers for
msrA.
A positive phage was cloned by plaque hybridizations [13] using the
digoxigenin-labelled (Dig PCR labelling kit, Roche, Mannheim, Ger-
many) fragment as a probe. The positive phage was then converted
into a plasmid by infecting an overnight culture (31‡C) of the Escher-
ichia coli strain BM25.8. The insert of the plasmid isolated from the E.
coli cells was sequenced at least twice in both directions.
2.2. Tissue distribution of hmsrA mRNA
Tissue distribution was tested by RNA dot blot analysis. The PCR
fragment mentioned above was labelled with [K-32P]dCTP by random
priming (Ready-To-Go DNA Labelling Beads (-dCTP), Amersham
Pharmacia Biotech, Braunschweig, Germany) according to the proto-
col supplied with the kit. The hmsrA DNA probe was hybridized to a
human multiple tissue expression array ¢lter (MTE, Clontech, Heidel-
berg, Germany) loaded with poly A RNA from 76 di¡erent human
tissues and eight di¡erent control RNAs and DNAs, following the
instructions of the supplier. The MTE array was exposed to an X-ray
¢lm for 3 days, the ¢lm was scanned and the data processed with
IgorPro software (WaveMetrics, Lake Oswego, OR, USA).
2.3. Assay of enzymatic activity and immunochemistry
hMsrA protein was obtained by means of the glutathione-S-trans-
ferase (GST) gene fusion system (Pharmacia Biotech, Freiburg, Ger-
many). A PCR fragment comprising the hmsrA open reading frame
was cloned into the pGEX-5X-1 vector and hMsrA was overexpressed
in E. coli BL21. Cells were harvested, resuspended in protease inhib-
itor (aprotinin, E-64, leupeptin, Pefabloc SC, pepstatin, all from
Roche Molecular Biochemicas, Mannheim, Germany) containing
TBN-150-bu¡er (25 mM Tris, 150 mM NaCl, 10 mM 2-mercapto-
ethanol, pH 7.5), disrupted by repeated freezing and thawing, and
treatment with lysozyme (0.5 mg/ml). After lysis, 14 mM EDTA
and 0.35% Triton X-100 were added. The lysate was centrifuged
and the supernatant applied to glutathione agarose columns (Sigma).
The columns were washed with several volumes of TBN-150-bu¡er+
1% Triton X-100, followed by 50 mM Tris, 150 mM NaCl, 10 mM
2-mercaptoethanol. When the washing bu¡er was protein free, the
GST-hMsrA fusion protein was eluted with 10 mM glutathione
(reduced), 33 mM NaOH, 2.5 mM Tris, pH 8.0. The purity of the
protein was checked by SDS-PAGE and the protein concentration
determined using the Bradford’s reaction (Coomassie Plus Protein
Assay Reagent kit, Pierce).
The assay for MsrA activity was performed essentially as described
previously [14]. Brie£y, the puri¢ed fusion protein was incubated in a
bu¡er containing 20 mM Tris-Cl, pH 7.4, 15 mM dithiothreitol and
0.3 mM [3H]N-acetyl methionine sulfoxide. After 20 min of incuba-
tion, the mixture was acidi¢ed and the [3H]N-acetyl methionine
formed was extracted with ethyl acetate and the radioactivity in the
organic phase determined.
Antibodies raised against bMsrA [10] were used for comparing the
binding speci¢city to puri¢ed bMsrA and hMsrA by Western blot
analysis.
2.4. Oocyte expression and solutions
hmsrA was cloned into the oocyte expression vector pGEM-HE
[15]. RNAs of hmsrA and ShC/B [16,17] were in vitro transcribed
using the T7 and SP6 mMessage mMachine kits (Ambion, Austin,
USA), respectively. Stage V oocytes were surgically obtained from
Xenopus laevis anaesthetized with 0.2% tricaine in ice water. Oocytes
were injected with 50 nl of RNAs encoding ShC/B potassium channels
and hMsrA (mRNA ratio ShC/B:hmsrA = 1:6).
2.5. Electrophysiological recording and data analysis
Recording of whole oocyte currents was performed at room temper-
ature (19^22‡C) with a two-electrode voltage clamp ampli¢er (Turbo
Tec 10CD, npi electronic, Tamm, Germany), one day after mRNA
injection. Electrodes were ¢lled with 2 M KCl and had resistances
between 0.6 and 1.0 M6. The extracellular bath contained 107 mM
NaCl, 10 mM KCl, 1.8 mM CaCl2, 10 mM HEPES (pH 7.2, adjusted
with NaOH). Data were collected with the Pulse+PulseFit acquisition
package (HEKA Elektronik, Lambrecht, Germany) running on an
Apple Macintosh computer. Data analysis was performed with Pulse-
Fit, PulseTools (HEKA Elektronik) and IgorPro (WaveMetrics).
3. Results and discussion
3.1. Cloning of hMsrA
An hmsrA encoding cDNA was cloned from a human lung
cDNA library. The open reading frame consists of 708 nucleo-
tides and is translated into 235 amino acids that share 88%
identity to bMsrA (Fig. 1, accession number: pending). Com-
Fig. 1. Alignment of the hMsrA protein sequence, deduced from the sequence of a cloned cDNA, to MsrA from B. taurus (bMsrA) [11].
hMsrA (235 amino acids) shares 207 (88%) identical and 219 (93%) similar residues with bMsrA (233 amino acids). Periods denote identical
residues and dashes denote gaps in the alignment.
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pared to bMsrA, hMsrA contains two additional amino acids
in the N-terminus and harbors ¢ve consensus sites for putative
protein kinase C phosphorylation and four for casein kinase
II.
hMsrA was also cloned from a human heart cDNA library
(5P-Stretch PLUS cDNA library in Vgt10, Clontech, Palo
Alto, USA) and from a human brain cDNA library (Mara-
thon-Ready cDNA library, Clontech) by PCR. The DNA
sequences of these clones are identical to the sequence cover-
ing the open reading frame obtained from the human lung
cDNA library.
Immunoblot analysis was performed on the puri¢ed GST-
hMsrA protein using antibodies raised against bMsrA. The
results showed that these antibodies reacted about as well to
the human protein as to the bovine (data not shown), thus
corroborating the very high sequence homology.
3.2. Tissue distribution
The levels of hmsrA mRNA in di¡erent human tissues were
determined by hybridization of a 32P-labelled cDNA probe to
tissue poly A RNA blots (Fig. 2). Very little non-speci¢c
hybridization background was observed (column 12).
Except for leukemic/lymphomic cells (A10, C10-F10),
hmsrA mRNA could be detected in all human tissues with
highly varying expression levels. Maximum expression was
found in human kidney (A7) and cerebellum (A2, B2), fol-
lowed by liver (A9, staining about 50% of kidney), heart ven-
tricles (E4, F4), bone marrow (G7) and hippocampus (F2) in
descending intensity. Performing heterologous hybridization
of a bmsrA cDNA probe to a rat multiple tissue RNA blot,
Moskovitz et al. [11] obtained similar results with the highest
expression in kidney, followed by liver, testis, heart, lung and
brain. Such a high expression in human as well as in rat
kidney and liver tissue implies an important function of
MsrA in the repair of oxidative damage.
hmsrA expression does not only vary among di¡erent or-
gans, it also shows a speci¢c pattern within a given organ as
can be seen for brain (columns 1^3) and heart (column 4). In
the human nervous system, the strongest signal for hmsrA
mRNA was observed in the cerebellum (A2, B2), followed
by hippocampus (F2), temporal lobe (F1) and spinal cord
(E3). Lowest expression in the brain was observed in pons.
Judged by the intensity of the staining, the expression in pons
was only about 10% of that in cerebellum. A comparable
expression pattern was reported for rat brain [10], where im-
munocytochemical staining revealed the highest MsrA expres-
sion in the cerebellum.
In fetal tissue, the highest expression was observed in liver
(D11), where it was in the same range as in adult liver (A9).
This observation correlates with the fact that fetal liver is
already metabolically active. The most pronounced di¡erence
between adult and fetal human tissue, regarding hmsrA ex-
pression, was observed in the kidney. Expression in fetal kid-
ney (C11) is about 14% of the expression level in adult kidney
Fig. 2. Tissue distribution of hmsrA tested by RNA dot blot analysis. A 32P-labelled hmsrA DNA probe was hybridized to a human MTE ar-
ray (Clontech). hmsrA mRNA is expressed in all tested human tissues, with the highest mRNA levels in adult kidney and cerebellum, followed
by liver, heart ventricles, bone marrow and hippocampus. A1: whole brain, B1: cerebral cortex, C1: frontal lobe, D1: parietal lobe, E1: occipi-
tal lobe, F1: temporal lobe, G1: paracental gyrus of cerebral cortex, H1: pons, A2: cerebellum left, B2: cerebellum right, C2: corpus callosum,
D2: amygdala, E2: caudate nucleus, F2: hippocampus, G2: medulla oblongata, H2: putamen, A3: substantia nigra, B3: nucleus accumbens,
C3: thalamus, D3: pituitary gland, E3: spinal cord, A4: heart, B4: aorta, C4: atrium left, D4: atrium right, E4: ventricle left, F4: ventricle
right, G4: interventricular septum, H4: apex of the heart, A5: esophagus, B5: stomach, C5: duodenum, D5: jejunum, E5: ileum, F5: ileoce-
cum, G5: appendix, H5: colon ascending, A6: colon transverse, B6: colon descending, C6: rectum, A7: kidney, B7: skeletal muscle, C7:
spleen, D7: thymus, E7: peripheral blood leukocyte, F7: lymph node, G7: bone marrow, H7: trachea, A8: lung, B8: placenta, C8: bladder,
D8: uterus, E8: prostate, F8: testis, G8: ovary, A9: liver, B9: pancreas, C9: adrenal gland, D9: thyroid gland, E9: salivary gland, F9: mam-
mary gland, A10: promyelocytic leukemia HL-60, B10: Hela S3, C10: chronic myelogenous leukemia K-562, D10: lymphoblastic leukemia
MOLT-4, E10: Burkitt’s lymphoma Raji, F10: Burkitt’s lymphoma Daudi, G10: colorectal adenocarcinoma SW480, H10: lung carcinoma
A549, A11: fetal brain, B11: fetal heart, C11: fetal kidney, D11: fetal liver, E11: fetal spleen, F11: fetal thymus, G11: fetal lung, A12: yeast
total RNA, B12: yeast tRNA, C12: E. coli rRNA, D12: E. coli DNA, E12: poly r(A), F12: human C0t-1 DNA, G12: human DNA (100 ng),
H12: human DNA (500 ng).
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(A7). This di¡erence correlates with the very low ¢ltration
rate of fetal kidney. Furthermore, the ability to concentrate
urine does not develop before birth. As it was shown in adult
rat, kidney MsrA expression is highest in the medulla, the
urine-concentrating section [10]. Thus, a possible function of
MsrA may be to protect proteins expressed in the kidney from
damage by oxidants in highly concentrated urine.
The lack of hMsrA expression in leukemia or lymphoma
cell lines (A10, C10-F10) is surprising since normal peripheral
blood leukocytes do express hMsrA (E7). The lack of MsrA
could make leukemic cells more sensitive to oxidative stress
than normal cells. This hypothesis is supported by the recent
observation that, under oxidative stress, the survival rate of
human T-lymphocytes MOLT-4, which normally do not ex-
press hMsrA (Fig. 2, D10), can be increased by stable trans-
fection with bmsrA [12]. A decreased resistance of leukemic/
lymphomic cells to oxidative stress could be of therapeutic
interest. Though it is tantalizing to speculate that a lack of
MsrA expression may be a general property of tumor cell
lines, MsrA is expressed in some tumor lines. In colorectal
adenocarcinoma cells (G10) or lung carcinoma cells (H10),
the hmsrA expression level is in about the same range as in
the corresponding normal tissue (colon/rectum: H5, A6, B6,
C6; lung: A8). In accordance with these results, we could
detect hmsrA RNA by reverse transcription-PCR in the hu-
man neuroblastoma cell line SH-SY5Y (data not shown).
3.3. Enzymatic activity of recombinant GST-hMsrA fusion
protein
For an in vitro test of the enzymatic activity of hMsrA, we
generated a GST-hMsrA fusion protein and puri¢ed it after
overexpression in E. coli. The catalytic activity of hMsrA in
reducing methionine sulfoxide was assayed by using [3H]N-
acetyl methionine sulfoxide as substrate and dithiothreitol as
electron donor. After 20 min of incubation at 37‡C, 9.7 pmol
of [3H]N-acetyl methionine per pmol GST-hMsrA fusion pro-
tein was formed, demonstrating that the activity of hMsrA is
in the same order of magnitude as the activity reported for
bMsrA [11].
3.4. Co-expression of hMsrA with ShC/B potassium channels
The function of hMsrA was also tested in vivo by assaying
its e¡ect on the function of the voltage-dependent A-type
potassium channel ShC/B. Ciorba et al. [8] have shown that
ShC/B, heterologously expressed in Xenopus oocytes, is regu-
lated by oxidation/reduction of a critical methionine residue at
position 3 in the N-terminus of the polypeptide (amino acid
residue 3). Oxidation of this methionine slows down the de-
polarization-induced N-type inactivation. Di¡erential oxida-
tion states of the residue in di¡erent channel proteins are
responsible for the large variability in the inactivation time
course. It was also shown that Xenopus oocytes have a low
endogenous MsrA activity and that heterologous expression
of the enzyme dramatically accelerates the N-type inactivation
time course and reduces variability. Thus, we used the inacti-
vation time course of the ShC/B channel as a functional assay
of the hMsrA activity. Indeed, co-expression of the channel
with hMsrA accelerated N-type inactivation and reduced its
variability (Fig. 3). This potency of hMsrA to a¡ect the A-
type current suggests a function as a regulator in cellular
excitability.
The high expression of hMsrA in those tissues often re-
garded as ‘house keeping tissues’, such as kidney and liver,
in general supports the idea that hMsrA is involved in protein
repair mechanisms. Di¡erential expression levels of hMsrA
between fetal and adult heart (Fig. 2, B11-A4) and kidney
(C11-A7) are also in line with the developmental regulation
of MsrA in these tissues. Relatively high expression levels in
speci¢c regions of the brain, namely hippocampus (Fig. 2, F2)
and cerebellum (A2, B2), indicate that hMsrA may participate
in the brain-speci¢c tasks, such as learning and memory. In
conclusion, these results support the hypothesis of the dual
role for the enzyme hMsrA in repair of oxidative damage as
well as in regulation of speci¢c protein functions.
Acknowledgements: We thank A. RoMner and S. Arend for technical
assistance. This work was supported by the DFG (He2993) and NIH
(GM 57654).
Fig. 3. Current recordings from Xenopus oocytes expressing ShC/B potassium channels. Currents were elicited by depolarization to +40 mV
from a holding potential of 390 mV. The upper panels show superimposed scaled current traces from multiple oocytes (each trace = one
oocyte) injected with the channel mRNA alone (left) and from oocytes injected with channel and hMsrA mRNA (right). The lower panels
show the corresponding mean currents and the S.D.s (gray). n gives the number of oocytes measured. Under control conditions, the inactiva-
tion time course is slow and displays a large cell to cell variability. Upon co-expression with hMsrA, inactivation is faster and the variability
among di¡erent cells is markedly reduced.
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